First GLP-1 Generic Launched; 5:2 Intermittent Fasting Win; WHO’s Ozempic Warning

Teva Pharmaceuticals announced the launch of the first authorized GLP-1 receptor agonist generic of liraglutide 1.8 mg injection (Victoza) in the U.S.

Combining 3-mg liraglutide (Saxenda) with exercise yielded more weight loss compared with either alone, and preserved bone health. (JAMA Network Open)

The Environmental Protection Agency’s rule limiting per- and polyfluoroalkyl substances (PFAS) — also known as forever chemicals — in drinking water is facing legal challenges. (NPR)

The American Diabetes Association (ADA), along with several other organizations, released new consensus guidance for monitoring people with islet autoantibody-positive pre-stage 3 type 1 diabetes. Catch up on the latest news from the ADA’s annual meeting here. (Diabetes Care)

A 5:2 intermittent fasting plan — 2 nonconsecutive fasting days and 5 days of habitual intake — with meal replacement achieved better glycemic control at 16 weeks for patients with early type 2 diabetes compared with metformin or the SGLT2 inhibitor empagliflozin (Jardiance). (JAMA Network Open)

The WHO issued a warning on counterfeit versions of semaglutide (Ozempic) showing up in the drug supply.

Lexicon Pharmaceuticals resubmitted its new drug application for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in patients with type 1 diabetes and chronic kidney disease. The FDA initially rejected approval in 2019 following a split advisory committee vote.

Babies born to mothers without diabetes on GLP-1 medications in the 90 days before pregnancy were 21% more likely to be admitted to the neonatal intensive care unit compared with those born to mothers not taking these agents. (Epic Research)

South Africa’s public healthcare system has run out of insulin pens as the global supply of injectables has shifted to support the demand for new GLP-1 drugs like semaglutide (Ozempic, Wegovy). (New York Times)

Eli Lilly is suing six more med spas and wellness centers for selling products claiming to contain the weight-loss agent tirzepatide (Mounjaro). (Reuters)

Novo Nordisk is planning to build a $4.1 billion facility in North Carolina as demand for weight-loss drugs continues to grow. (The Hill)

Please enable JavaScript to view the

comments powered by Disqus.